Similar articles

• Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.

  Korbet SM. Korbet SM. Kidney Int Suppl. 1993 Feb;40:S111-9. Kidney Int Suppl. 1993. PMID: 8445832 Review. No abstract available.
• Seizures in dialysis patients treated with recombinant erythropoietin.

  Beccari M, Romagnoni M, Sorgato G. Beccari M, et al. Nephrol Dial Transplant. 1995;10(3):423-4. Nephrol Dial Transplant. 1995. PMID: 7792048 No abstract available.
• Indications and contraindications for recombinant human erythropoietin treatment. Results in hemodialysis patients.

  Samtleben W, Baldamus CA, Bommer J, Grützmacher P, Nonnast-Daniel B, Scigalla P, Gurland HJ. Samtleben W, et al. Contrib Nephrol. 1989;76:193-200; discussion 212-8. Contrib Nephrol. 1989. PMID: 2684521 Clinical Trial. No abstract available.
• [Human recombinant erythropoietin in treatment of uremic anemia in children with continual ambulatory peritoneal dialysis].

  Litwin M, Boguszewska-Baczkowska A, Jelonek A. Litwin M, et al. Pol Tyg Lek. 1994 Feb 7-14;49(6-7):135-6. Pol Tyg Lek. 1994. PMID: 8090665 Polish.
• Adverse effects of therapy for the correction of anemia in hemodialysis patients.

  Watson AJ. Watson AJ. Semin Nephrol. 1989 Mar;9(1 Suppl 1):30-4. Semin Nephrol. 1989. PMID: 2648519 Review.